Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-acetyl cysteine (NAC), alpha lipoic acid (ALA), and liposomal glutathione represent a combination of potent antioxidant compounds intended to enhance cellular defense against oxidative stress and inflammation. N-acetyl cysteine serves as a precursor for the synthesis of glutathione, the body's primary endogenous antioxidant. Alpha lipoic acid is a versatile dithiol compound that can scavenge free radicals and regenerate other antioxidants like vitamins C and E. Liposomal glutathione provides a direct, encapsulated form of the tripeptide to improve systemic bioavailability. This combination has been explored for its potential to mitigate oxidative stress-induced damage in dermatological conditions such as atopic dermatitis. However, it is important to note that the specific Phase 3 clinical trial context often associated with Merz North America in atopic dermatitis (MSRD-100) specifically evaluates desoximetasone, a topical corticosteroid, rather than this antioxidant mixture, suggesting a discrepancy between the drug name and the clinical trial context provided.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-acetyl cysteine + alpha lipoic acid + liposomal glutathione (Merz).